Market access risk in gastroenterology and hepatology

Two very different reimbursement stories share this page. In inflammatory bowel disease — Crohn's disease and ulcerative colitis — the question is no longer whether a biologic will be paid for but where in the queue it stands: behind the biosimilar anti-TNF medicines that now cost a fraction of their original price, and among a dozen newer options that payers sequence rather than choose. In the liver, by contrast, payers are meeting diseases that until recently had no drug at all — fatty liver disease, the rare cholestatic conditions, hepatitis D — and are being asked to pay for benefits measured in biopsies and blood tests years before anyone can show a liver saved. This page brings together MARA's independent assessments of reimbursement risk across both.

What payers ask in gastroenterology and hepatology

Where in the sequence is the drug reimbursed? In bowel disease the payer's first answer is a step: biosimilars first, then the newer classes for those who fail or cannot take them. The reimbursed position — first line, second, or after two failures — matters more to a drug's commercial life than the approval itself, and it is set by the payer, not the label.

Is the endpoint the gut, or the patient? Trials now report healing seen through the endoscope as well as symptoms. Payers value both, but ask which one the price is for: a drug that heals the lining without changing how the patient feels, or one that changes the patient's year, with fewer flares, surgeries and hospital stays.

Can a liver biopsy carry a price? The new liver drugs are approved on changes in tissue and blood — fibrosis stages, enzyme levels, bile acids — because the outcomes they are meant to prevent, cirrhosis and transplant, take years to appear. Payers reimburse on those surrogates narrowly and conditionally, and wait for the outcome data before they widen.

What does the alternative cost? For the rare conditions here the alternative is often not a drug but a service: parenteral nutrition for short bowel syndrome, transplant for end-stage liver disease, repeated hospital care for uncontrolled disease. Payers weigh the new drug against that bill, which can make an expensive medicine look reasonable — or a cheaper one look unnecessary.

The MARA record in gastroenterology and hepatology

Gastroenterology and hepatology holds nearly twenty dated assessments in the MARA catalogue: the interleukin, JAK and S1P classes in ulcerative colitis and Crohn's disease, primary biliary cholangitis and its itch, chronic hepatitis D, metabolic liver disease, short bowel syndrome and eosinophilic oesophagitis. Each report answers the same payer questions, carries its "as of" date, and stays on the record — when the evidence moves, a newer vintage replaces the older one visibly, never silently. Assessments are produced on MARA's own initiative for awareness; the current MARA Rating for any drug is available on request.

Current assessments (17)

Earlier assessments (each replaced by a newer version)

Selected commentary

Mirum gains a hepatitis D drug in a $620M buyout of Bluejay

For how a MARA Rating is built, see the methodology and what a MARA Rating is. To request the current rating for any drug in this area, use the contact form.